Alcami Corporation
Alcami is a contract development and manufacturing organization (CDMO) that helps pharmaceutical and biotechnology companies advance drugs from early development through commercial supply. Its services span analytical and laboratory testing, formulation and drug-product development, sterile fill-finish manufacturing, and stability storage for both small molecules and biologics. With roots going back more than four decades, the company is headquartered in Durham, North Carolina and operates a network of U.S. facilities.
Company profile compiled from public sources (company filings, rating-agency reports, and press releases) — distinct from the SEC Schedule-of-Investments pricing data below.
Lenders
Alcami Corporation is held by 5 BDC lenders in our parsed SEC filings: AGTC, BKCC, KBDC, MFIC, TCPC.
Cross-lender loan pricing
Each row is one debt tranche at the BDC’s most recent filing that holds this borrower, widest spread first. Mark is the position’s fair value as a percent of par (100 = par). Spread is shown in basis points over the benchmark in the Rate column, normalized from each filing’s as-reported units — rows quoting different benchmarks are still not directly comparable. Compare like-for-like: a second-lien tranche, a different vintage, or an older filing should price wider even when the credit view is identical — check the Type and Filing columns before reading a gap as disagreement. Source: SEC EDGAR (public).
| BDC | Type | Rate | Spread (bps) | Mark (% of par) | Fair Value | Maturity | Filing |
|---|---|---|---|---|---|---|---|
| KBDC | 1L Sr Secured | PIK | 715 | 100.0 | $11M | 2028-12-21 | 2026-05-11 |
| TCPC | 1L Sr Secured | SOFR | 715 | 100.0 | $8M | 2028-12-21 | 2026-05-07 |
| KBDC | 1L Sr Secured | PIK | 710 | 100.0 | $489K | 2028-12-21 | 2026-05-11 |
| KBDC | 1L Sr Secured | PIK | 710 | 100.0 | $836K | 2028-12-21 | 2026-05-11 |
| MFIC | 1L Sr Secured | SOFR | 710 | 96.2 | $329K | 2028-12-21 | 2026-05-06 |
| MFIC | 1L Sr Secured | SOFR | 710 | 98.8 | $8M | 2028-12-21 | 2026-05-06 |
| MFIC | 1L Sr Secured | SOFR | 710 | 98.8 | $578K | 2028-12-21 | 2026-05-06 |
| TCPC | 1L Sr Secured | SOFR | 710 | 100.0 | $624K | 2028-12-21 | 2026-05-07 |
| TCPC | Debt | SOFR | 710 | 100.0 | $365K | 2028-12-21 | 2026-05-07 |
| AGTC | 1L Sr Secured | SOFR | 700 | 100.0 | $4M | 2028-12 | 2026-05-12 |
| BKCC | 1L Sr Secured | SOFR | 700 | 102.0 | $2M | 2028-12-21 | 2024-03-05 |
| BKCC | 1L Sr Secured | SOFR | 700 | — | $4K | 2028-12-21 | 2024-03-05 |
| BKCC | 1L Sr Secured | SOFR | 700 | — | — | 2028-12-21 | 2024-03-05 |
Marks reflect each BDC’s own fair-value estimates as reported to the SEC, not traded prices. Private-credit loans are predominantly Level 3 under ASC 820 — valued from unobservable inputs and determined in good faith by each BDC’s board, so figures are estimates as of the filing date and are not directly comparable across managers. Informational only; not investment advice or a valuation.
Ownership & deal activity
Headlines mentioning Alcami Corporation
Reading this table
When two business development companies lend to the same borrower, comparing how each marks the loan is a starting question, not a verdict. In plain English: a wider spread (e.g. S+575 vs S+525) or a lower mark (e.g. 96 vs 100 cents on the dollar) can mean that lender is pricing in more risk — but marks can also differ for reasons other than a credit view: a different tranche (second lien should price wider than first lien on the same company), a different vintage or entry point, an older filing date, or each manager’s own fair-value methodology. Compare like-for-like — check the Type and Filing columns before reading a gap as disagreement. Each row is one debt position at one BDC’s most recent filing. Source: SEC EDGAR Schedule of Investments (public).
Want to read these numbers like an analyst? Free Oxford Ledge lessons: reading a BDC’s Schedule of Investments, key credit metrics, and the Five Cs of credit analysis.